HUMAX-INFLAM/MDX-018 REPORTS POSITIVE SAFETY/EFFICACY
DATA.
Genmab A/S (CSE: GEN) and Medarex Inc. (Nasdaq: MEDX) has announced
encouraging safety and efficacy data from a Phase I/II trial using
HuMax(tm)-Inflam/MDX-018 to treat patients suffering from an . . .
KEREOS/UNIVERSITY PROJECT FUNDED BY $7.3 MILLION GRANT.
Kereos, St. Louis, a biotechnology company developing targeted
therapeutics and imaging agents for the detection and treatment of
cancer and cardiovascular disease, has extended its research . . .
UNIVERSITY DEVELOPING STEROLS FOR CHOLESTEROL-BLOCKING.
Microfluidics, the operating subsidiary of MFIC Corporation (OTCBB:
MFIC), has announced that University of Massachusetts Lowell scientists
are using Microfluidizer(R) materials processing . . .
BCX-1777 GETS ORPHAN DRUG DESIGNATION FOR 2 MORE
INDICATIONS.
BioCryst Pharmaceuticals, Inc. (Nasdaq NM: BCRX), Birmingham, Ala.,
has announced that forodesine hydrochloride, its lead anti-cancer
compound formerly known as BCX-1777 (forodesine), has been . . .
ALEXION REACHES AGREEMENT WITH FDA FOR PHASE III
ECULIZUMAB.
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), Cheshire, Conn., has
received written confirmation from the U.S. Food and Drug Administration
(FDA) indicating agreement with the two protocols . . .
GENZYME FILES FOR EUROPEAN APPROVAL OF MYOZYME.
Genzyme Corp. (NASDAQ:GENZ), Cambridge, Mass., has announced that
the EuropeanMedicines Agency (EMEA) has accepted its marketing
authorization application for Myozyme(R) (alglucosidase alfa), . . .
HUGO PACIFIC TO EXPLORE GENETIC DIVERSITY.
A coalition of scientists from Asian countries are organizing a
study of genetic diversity in Asian populations, the HUGO Pacific
Pan-Asian SNP Initiative, which will provide a detailed . . .
PROVECTUS FILES FDA IND FOR TREATMENT OF MALIGNANT
TUMORS.
Provectus Pharmaceuticals, Inc. (BULLETIN BOARD: PVCT), Knoxville,
Tenn., has filed an Investigational New Drug (IND) application for
Provecta(TM), an advanced drug therapy designed to treat . . .
ASCEND FILES PATENT FOR BENIGN BREAST DISEASE DRUG.
ASCEND Therapeutics, Herndon, Va., has filed a patent application
for both the pharmaceutical composition of TamoGel(tm)
(4-hydroxytamoxifen gel) and the gel's use for the treatment of
benign . . .
AGENSYS/GENENTECH SIGN COLLABORATION/LICENSE AGREEMENT.
Agensys, Inc., Santa Monica, Calif., a cancer biotechnology
company, has signed an agreement with Genentech Inc. (NYSE: DNA) for the
research, development and commercialization of therapeutic . . .
RIGEL INITIATES R406 CLINICAL TRIAL FOR RHEUMATOID
ARTHRITIS.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), South San Francisco, has
initiated a phase I clinical trial of R406, a product candidate for the
treatment of rheumatoid arthritis (RA). The goal of this . . .
MORPHOTEK GETS "TECHNOLOGY COMPANY OF THE YEAR"
AWARD.
Morphotek Inc., Exton, Pa. has been named "2004 Technology
Company of the Year" by the Greater Philadelphia Chamber of
Commerce. The award is based on a company's achievements, vitality,
creativity . . .
BIOMARIN GETS POSITIVE DATA FROM VIBRILASE PHASE 1B
TRIAL.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Novato, Calif. has
announced positive results from a Phase 1b clinical trial of
Vibrilase(TM) (vibriolysin), an investigational topical enzyme for . . .
PHARMION SELECTS MCKESSON TO DISTRIBUTE VIDAZA.
McKesson Corporation, a leading healthcare services company, has
been selected by global pharmaceutical manufacturer, Pharmion, to
distribute Vidaza(TM) (azacitidine for injectable suspension), the . . .
HYBRIDON'S OLIGONUCLEOTIDES SHOW POTENT ADJUVANT
ACTIVITY.
Hybridon, Inc. (AMEX: HBY), Cambridge, Mass., has presented
preclinical results illustrating that its 2nd generation
immunomodulatory oligonucleotide (IMO) compounds demonstrated potent
adjuvant . . .
MORPHOSYS EXTENDS AGREEMENT WITH CENTOCOR.
MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard
Segment; TecDAX) has announced the extension of its agreement with
Centocor Inc., a Johnson & Johnson company, until the end of 2007.
The . . .
EHEALTH INNOVATORS DRIVE HEALTH/PHARMACEUTICAL MARKETING.
Manhattan Research, LLC, New York, a healthcare marketing
information and services firm has identified a new group emerging in the
growing market of online health consumers: the eHealth Innovators. . . .
VERTA AWARDED GOVERNMENT GRANT TO EVALUATE SCV-07.
SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN), San Mateo, Calif.,
has announced that its collaborative partner, Verta, Ltd., has been
awarded a grant from the U.S. Government to evaluate the . . .
POWER3 GETS RIGHTS TO NEURODEGENERATIVE DISEASE BLOOD
TEST.
Power3 Medical Products, Inc. (OTCBB: PWRM), The Woodlands, Texas,
a leading proteomics company has secured the exclusive worldwide
licensing rights from Baylor College of Medicine for serum . . .
SOMALOGIC GETS RIGHTS TO DNA MODIFICATION PATENTS.
SomaLogic, Inc., Boulder, Colo., a privately held proteomics
company, has significantly expanded its intellectual property base by
acquiring an exclusive license to several key foreign and . . .
|
|